Results of 15  Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.

CONCLUSION: In this large cohort of intermediate-risk prostate cancer patients, 15 Gy HDR-BT boost plus EBRT results in durable biochemical control and low rates of ADT use for biochemical failure.
PMID: 31522882 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 11, 2019 Category: Radiology Authors: Martell K, Mendez LC, Chung HT, Tseng CL, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Wronski M, Szumacher E, Ravi A, Loblaw A, Morton G Tags: Radiother Oncol Source Type: research